News und Analysen

Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) both have Alzheimer's drugs that are in development and could obtain approval from the Food and Drug Administration (FDA) within the next 12 months

Inflation rates may finally be cooling down from last year's unnerving levels. However, prices are still rising at a pace above long-term averages, so consumers can't breathe easy just yet -- and

Deal or no deal? That's now the big question for investors concerning Amgen's (NASDAQ: AMGN) pending $28 billion acquisition of Horizon Therapeutics (NASDAQ: HZNP).

The Federal Trade Commission

Income investing is a tried-and-true investing strategy. This is because businesses that pay consistent and growing dividends to shareholders are often mature businesses that can't possibly reinvest

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

Big Pharma needs

Biotech stocks have been on a wild ride this year. For instance, the bellwhether SPDR S&P Biotech ETF (NYSEMKT: XBI) has been up by as much as 9%, and down by as much as 12%, during just the first

Shares of Horizon Therapeutics (NASDAQ: HZNP), a rare disease specialist, were down by 17.4% on heavy volume as of 10:14 a.m. ET Tuesday morning. The drugmaker's shares are falling after news broke

Johnson & Johnson (NYSE: JNJ) and UnitedHealth Group (NYSE: UNH) are considered great healthcare stocks to hold for the long term because of their size, steady cash flow, and above-average

Investors looking to secure a steadily growing passive income stream have all sorts of options, but few are easier to implement than buying dividend-paying stocks. That said, not every dividend

Shares of Sarepta Therapeutics (NASDAQ: SRPT) were skyrocketing 24.9% higher as of 10:37 a.m. ET on Monday. The huge gain came after the company announced Friday evening that a U.S. Food and Drug

Many of the greatest investors of all time could be considered value investors. A value investing strategy centers around buying stocks at less than their fair value -- often much less.

One stock

Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) are both keen to compete in the market for Alzheimer's disease therapies. Biogen's prior attempt at an Alzheimer's medicine to hit the market was a

Just 14% of drugs in development (according to a 2018 study) ever make it to market, so investing in pharmaceuticals is a bit of a shot in the dark. And smaller companies that lack any approved

Biogen (NASDAQ: BIIB) has been a polarizing stock to own over the past few years. Aduhelm's accelerated approval sent the stock soaring a few years ago, but after controversy surrounding its

Stryker (NYSE: SYK) and Medtronic (NYSE: MDT) are a pair of the biggest and most important medical-device and supply companies out there, but they're a bit different in the stability of the dividend

Despite another less-than-stellar Consumer Price Index report and more volatility among regional bank stocks, growth equities, on balance, were on the upswing this week. The tech-heavy Nasdaq

Shares of the rare disease juggernaut Sarepta Therapeutics (NASDAQ: SRPT) fell by 12.6% through the first three and a half days of trading this week, according to data provided by S&P Global Market

Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are two healthcare companies aiming to produce a vaccine for the respiratory syncytial virus (RSV). In trials, their vaccine candidates have been

Eli Lilly (NYSE: LLY) has a potential Alzheimer's treatment in donanemab that shows a lot of promise. The company reported data from a recent trial which demonstrated some encouraging results, and

Medtronic (NYSE: MDT) is a massive business that's changing rapidly now to keep up with shifts in its markets and an evolving global economy -- all of which can make it a bit difficult for observers

Vertex Pharmaceuticals (NASDAQ: VRTX) is already a rock star in the world of cystic fibrosis (CF) treatment. The company's drugs have been life-changing for children and adults living with the

Economists at the U.S. Federal Reserve recently uttered the dreaded "R" word. They are now predicting a recession will come later this year. Investors have been bracing for this possibility for a

Shares of the developmental gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) were up by 12.4% on sky-high volume as of 1:46 p.m. ET Tuesday afternoon. The big gain came in response to the bio

Eli Lilly (NYSE: LLY) and Merck (NYSE: MRK) have seen their shares rise by over 17% and 5%, respectively, this year while the S&P 500 Health Care Sector Index has dropped 1.7%. What's interesting